Enveric Biosciences, Inc. is a biotechnology company focused on developing novel neuroplastogen therapeutics for neuropsychiatric disorders. The company has established a portfolio of proprietary molecules, known as The Psybrary™, through its discovery and development platform and collaborations with global institutions. Enveric is advancing its lead candidate, EB-003, which aims to provide a new treatment approach for challenging mental health conditions by promoting neuroplasticity without inducing hallucinations.
